Modality
ADC
MOA
KRASG12Di
Target
APOC3
Pathway
Cell Cycle
OCDEndometrial Ca
Development Pipeline
Preclinical
~Dec 2022
→ ~Mar 2024
Phase 1
Jun 2024
→ Jul 2027
Phase 1Current
NCT04048732
208 pts·Endometrial Ca
2024-06→2027-07·Recruiting
208 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-07-151.3y awayPh2 Data· Endometrial Ca
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
P1/2
Recruit…
Catalysts
Ph2 Data
2027-07-15 · 1.3y away
Endometrial Ca
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04048732 | Phase 1/2 | Endometrial Ca | Recruiting | 208 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| Zanutinib | Bristol-Myers Squibb | Phase 2/3 | APOC3 | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| ALN-5628 | Alnylam | Phase 1/2 | APOC3 | |
| INC-1582 | Incyte | Phase 1/2 | APOC3 |